Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Frédéric Di Fiore

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5237-2971, 0000-0001-7955-6594; OpenAlex author ID A5103607071. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… Co-author DOI 10.1016/j.eclinm.2026.103998↗
  2. Relative dose intensity of gemcitabine-nab-paclitaxel combination as second-line or more in locally advanced or metastatic pancreatic adenocarcinoma. Last author DOI 10.1016/j.clinre.2025.102583↗
  3. New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial. Co-author DOI 10.1097/sla.0000000000006468↗
  4. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  5. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  6. FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Co-author DOI 10.1177/17588359211029825↗
  7. "Laparoscopic Para-Aortic Lymph Node Sampling" First Approach for Pancreatic Adenocarcinoma as an Oncological Practice. Co-author DOI 10.1089/lap.2018.0775↗
  8. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  9. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis. Co-author DOI 10.1038/ajg.2012.367↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lilian Schwarz · 4 shared papers, 2019–2025 · strength 0.68
  2. Jean‐Baptiste Bachet · 3 shared papers, 2018–2026 · strength 0.50
  3. David Tougeron · 2 shared papers, 2022–2026 · strength 0.33
  4. António Sá Cunha · 2 shared papers, 2019–2024 · strength 0.31
  5. Pierre Michel · 2 shared papers, 2013–2025 · strength 0.29
  6. Adrien Grancher · 1 shared paper, 2025 · strength 0.26
  7. Anthony Turpin · 2 shared papers, 2021–2022 · strength 0.23
  8. Carole Vitellius · 1 shared paper, 2026 · strength 0.22
  9. Yves Rinaldi · 1 shared paper, 2026 · strength 0.22
  10. Anna Pellat · 1 shared paper, 2026 · strength 0.22
  11. Côme Lepage · 1 shared paper, 2026 · strength 0.22
  12. Julien Taı̈eb · 1 shared paper, 2026 · strength 0.22
  13. Simon Pernot · 1 shared paper, 2026 · strength 0.22
  14. Déwi Vernerey · 1 shared paper, 2024 · strength 0.22
  15. Jean Pinson · 1 shared paper, 2024 · strength 0.22
  16. A Váry · 1 shared paper, 2021 · strength 0.12
  17. Astrid Lièvre · 1 shared paper, 2021 · strength 0.12
  18. Julien Edeline · 1 shared paper, 2021 · strength 0.12
  19. Christelle d’Engremont · 1 shared paper, 2022 · strength 0.11
  20. Gaël S. Roth · 1 shared paper, 2022 · strength 0.11
  21. Tullio Piardi · 1 shared paper, 2022 · strength 0.11
  22. Mathias Brügel · 1 shared paper, 2022 · strength 0.11
  23. Mehdi El Amrani · 1 shared paper, 2022 · strength 0.11
  24. Christophe Borg · 1 shared paper, 2022 · strength 0.11
  25. Stéphanie Truant · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.